[Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.]

Area of Science:

• Oncology
• Endocrinology
• Pathophysiology

Background:

• Hypercalcemia is a significant predictor of poor prognosis and mortality in cancer patients.
• Malignancy-associated hypercalcemia (MAH) presents a critical clinical challenge.
• Understanding MAH's mechanisms is crucial for effective patient management.

Purpose of the Study:

• To provide a concise overview of the pathology, etiology, and management of malignancy-associated hypercalcemia (MAH).
• To categorize the primary types of MAH for clearer understanding.
• To outline standard therapeutic approaches for MAH.

Main Methods:

• Review of existing literature on malignancy-associated hypercalcemia.
• Classification of MAH into humoral hypercalcemia of malignancy (HHM) and local osteolytic hypercalcemia (LOH).
• Summary of current treatment strategies.

Main Results:

• MAH is categorized into HHM (systemic soluble factor) and LOH (local bone resorption).
• Both HHM and LOH contribute to elevated serum calcium levels in cancer patients.
• Standard treatment involves hydration and antiresorptive agents.

Conclusions:

• Malignancy-associated hypercalcemia requires prompt recognition and management.
• Effective treatment strategies include hydration and antiresorptive medications.
• Addressing MAH can improve patient prognosis and reduce mortality.